Robert W. Baird Forecasts Strong Price Appreciation for Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience (NASDAQ:TWST) had its target price boosted by stock analysts at Robert W. Baird from $46.00 to $48.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 16.76% from the company’s previous close.

A number of other brokerages have also commented on TWST. Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Finally, Barclays reduced their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and a consensus target price of $51.78.

Twist Bioscience Price Performance

NASDAQ TWST opened at $41.11 on Tuesday. Twist Bioscience has a 1-year low of $23.07 and a 1-year high of $60.90. The company has a market capitalization of $2.41 billion, a P/E ratio of -10.76 and a beta of 1.78. The business has a 50 day moving average price of $43.93 and a 200 day moving average price of $46.15.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,730 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the transaction, the chief executive officer now owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Paula Green sold 3,310 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $143,025.10. Following the transaction, the senior vice president now owns 84,585 shares of the company’s stock, valued at $3,654,917.85. This trade represents a 3.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock worth $4,391,151 in the last 90 days. 3.92% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TWST. Signaturefd LLC grew its stake in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the period. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience during the 2nd quarter valued at about $43,000. Blue Trust Inc. increased its stake in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience during the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.